After pulling the plug on its first IPO attempt, ADC Therapeutics tried its luck during a pandemic. That gamble has paid off—the cancer drug developer reeled in $233 million in its Wall Street debut, outraising its original goal by more than $80 million. The proceeds will push the company’s lead programs through pivotal phase 2 studies. These include loncastuximab tesirine, nicknamed “lonca,” an antibody-drug conjugate targeting CD19 that the company is testing in patients with relapsed diffuse large B-cell lymphoma. Source: Fierce Biotech 15/5/2020